On Air Now

Listen

Listen Live Now » 92.5 FM Sioux Falls, SD

Weather

Current Conditions(Sioux Falls,SD 57104)

More Weather »
50° Feels Like: 50°
Wind: E 9 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Today

Mostly Sunny 70°

Tonight

Clear 46°

Tomorrow

Mostly Sunny 73°

Alerts

Pfizer gets Celebrex patent extension, sues generic companies

The entrance of Pfizer World headquaters in New York City, August 31, 2003. REUTERS/Jeff Christensen
The entrance of Pfizer World headquaters in New York City, August 31, 2003. REUTERS/Jeff Christensen

(Reuters) - U.S. regulators granted Pfizer Inc a reissued patent on its multibillion-dollar Celebrex pain drug that extends its marketing exclusivity until early December 2015, the company said on Tuesday.

That will give Pfizer an additional 1 1/2 years of selling a drug that had U.S. sales of more than $1.7 billion in 2012, before cheaper generic versions begin to hit the market at the end of 2015. Branded drugs can quickly lose upwards of 80 percent of sales once multiple generic versions become widely available.

The original basic patent for Celebrex - known chemically as celecoxib - expires on May 30, 2014, including six months of pediatric exclusivity for testing the drug in children. But the U.S. Patent & Trademark Office agreed to the reissued patent covering methods of treating arthritis and other approved conditions, Pfizer said.

Pfizer said it filed lawsuits against several generic drugmakers that are seeking permission from the U.S. Food and Drug Administration to sell a generic version of the drug in the United States beginning in May 2014.

Pfizer said it sued Teva Pharmaceutical Industries Ltd; Mylan Inc; Watson Pharmaceuticals, which has since changed its name to Actavis Inc; Lupin Pharmaceuticals; and Apotex to try to prevent them from selling their generic Celebrex until the new patent expires on December 2, 2015.

Shares of Pfizer were up 1.4 percent at $28.09 in morning trading on the New York Stock Exchange.

(Reporting by Bill Berkrot; Editing by Lisa Von Ahn)

Comments